Bioinformatics analysis identifies precision treatment with paclitaxel for hepatocellular carcinoma patients harboring mutant tp53 or wild-type ctnnb1 gene

Jiunn Chang Lin, Tsang Pai Liu, Vivin Andriani, Muhammad Athoillah, Chih Yang Wang, Pei Ming Yang

研究成果: 雜誌貢獻文章同行評審

摘要

Hepatocellular carcinoma (HCC) is an aggressive and chemoresistant cancer type. The development of novel therapeutic strategies is still urgently needed. Personalized or precision medicine is a new trend in cancer therapy, which treats cancer patients with specific genetic alterations. In this study, a gene signature was identified from the transcriptome of HCC patients, which was correlated with the patients’ poorer prognoses. This gene signature is functionally related to mitotic cell cycle regulation, and its higher or lower expression is linked to the mutation in tumor protein p53 (TP53) or catenin beta 1 (CTNNB1), respectively. Gene–drug association analysis indicated that the taxanes, such as the clinically approved anticancer drug paclitaxel, are potential drugs targeting this mitotic gene signature. Accordingly, HCC cell lines harboring mutant TP53 or wild-type CTNNB1 genes are more sensitive to paclitaxel treatment. Therefore, our results imply that HCC patients with mutant TP53 or wild-type CTNNB1 genes may benefit from the paclitaxel therapy.
原文英語
文章編號1199
期刊Journal of Personalized Medicine
11
發行號11
DOIs
出版狀態已發佈 - 11月 2021

ASJC Scopus subject areas

  • 醫藥(雜項)

指紋

深入研究「Bioinformatics analysis identifies precision treatment with paclitaxel for hepatocellular carcinoma patients harboring mutant tp53 or wild-type ctnnb1 gene」主題。共同形成了獨特的指紋。

引用此